Linperlisib Combined With Chidamide in Patients With PTCL - Trial NCT06421948
Access comprehensive clinical trial information for NCT06421948 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Yanyan Liu and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yanyan Liu
Henan Cancer Hospital
Timeline & Enrollment
Phase 1/2
Jan 01, 2024
May 31, 2026
Primary Outcome
CRR
Summary
The goal of this clinical trial is to determine the maximum tolerated dose (MTD) of PI3Kฮด
 inhibitor linperlisib when combined with fixed dose of HDAC inhibitor chidamide in
 participants with peripheral T-cell lymphoma (PTCL), and to compare the combination of
 linperlisib and chidamide to standard CHOP (cyclophosphamide, doxorubicin/epirubicin,
 vincristine, and prednisone) regimen chemotherapy in the frontline treatment of PTCL to see
 which therapy is better.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06421948
Non-Device Trial